Abstract: FR-PO323
Utilization of the Nonsteroidal Mineralocorticoid Receptor Antagonist (MRA) Finerenone with or without Previous Steroidal MRA
Session Information
- Diabetic Kidney Disease: Clinical Modeling, Diagnosis, Education, and More
October 25, 2024 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Diabetic Kidney Disease
- 702 Diabetic Kidney Disease: Clinical
Authors
- Zheng, Zihe, Bayer US LLC, Whippany, New Jersey, United States
- Fatoba, Samuel T., Bayer US LLC, Whippany, New Jersey, United States
- Novin, Matthew, Bayer US LLC, Whippany, New Jersey, United States
- Guerrero, German, Bayer US LLC, Whippany, New Jersey, United States
- Wang, Yunxun, Bayer US LLC, Whippany, New Jersey, United States
- Farag, Youssef MK, Bayer US LLC, Whippany, New Jersey, United States
- Mckee, Connor W., Cobbs Creek Healthcare LLC, Newtown Square, Pennsylvania, United States
- Huang, Wei, Cobbs Creek Healthcare LLC, Newtown Square, Pennsylvania, United States
- Tian, Hongping, Cobbs Creek Healthcare LLC, Newtown Square, Pennsylvania, United States
- Singh, Rakesh, Bayer US LLC, Whippany, New Jersey, United States
- Du, Yuxian, Bayer US LLC, Whippany, New Jersey, United States
- Mares, Jon W., Bayer US LLC, Whippany, New Jersey, United States
- Lavagnino, Marco, Bayer US LLC, Whippany, New Jersey, United States
- Rockett, Drew, Bayer US LLC, Whippany, New Jersey, United States
- Sankaralingam, Karthik, Bayer US LLC, Whippany, New Jersey, United States
Background
Finerenone is an FDA-approved non-steroidal MRA indicated for reducing cardiovascular risk and slowing CKD progression in patients with CKD and T2D. Treatment inertia with nsMRA may stem from prior use of traditional steroidal MRAs (sMRA) that are known to be associated with increased hyperkalemia. To begin addressing this practice uncertainty, we described the key characteristics of finerenone users in real-world, with and without known prior sMRA use. We expect nsMRA use among eligible prior sMRA users.
Methods
We conducted retrospective study of finerenone users from July 2021 to December 2023 using the IQVIA Longitudinal Access and Adjudication Data. Adult patients with ≥ 12 months of continuous activity prior to their first filled finerenone claim date (index) were included. Patients with claims for both finerenone and sMRA on the same day were excluded. We described baseline demographics, comorbidities, and comedications of finerenone users by prior sMRA use status.
Results
The largest claim-based finerenone user cohort of 107,143 patients were included, among them 8,025 (7.5%) and 3,315 (3.15%) were prescribed sMRA within the past year and over a year, respectively, prior to initiating finerenone. The mean age was 67 with female percentage at 45-47% across subgroups. Those with prior sMRA prescription exhibited a 23-27% higher prevalence of HF and a 26-30% higher loop diuretic use. Comedication percentage for SGLT2i (47-51%) and GLP1RA (35-37%) remained consistent, regardless of prior sMRA use.
Conclusion
Our study shows that almost 11% of current finerenone users had prior or recent prescription of traditional sMRA. These patients exhibited different comorbidities and comedication profiles from those without prior sMRA prescription at the time of finerenone initiation. Future research should investigate the CV, kidney, and safety outcomes of finerenone users who recently used sMRA to inform clinical practice.
Funding
- Commercial Support – Bayer US LLC